You Position: Home > Paper
Change of the EGFR expression and downstream signal pathway in A549 cell treated with ZD1839
( views:349, downloads:32 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 7
- DOI:
- 10.3760/cma.j.issn.1006-9801.2007.07.005
- Key Word:
- 肺肿瘤;ZD1839;表皮生长因子受体
Abstract： 目的 研究ZD1839对A549细胞EGFR基因及其下游信号通路的影响.方法 利用MTT法检测ZD1839对A549细胞的生长抑制作用,Real-Time PCR检测EGFR及其下游信号分子表达的影响.结果 ZD1839可显著抑制A549细胞的生长,IC50在10 μmol/L左右.加入ZD1839后A549细胞EGFR基因表达为不加ZD1839的1.10倍,Ras基因为1.09倍,MAPK为0.521倍,PI3K为0.164倍,Akt为0.253倍.ZD1839对A549细胞的EGFR、Ras基因表达无影响,使MAPK、PI3K、Akt表达下调.结论 ZD1839抑制EGFR酪氨酸激酶活性,通过影响其下游PI3K/Akt、MAPK信号通路抑制A549细胞生长.
- [1]Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.[J].2001,25(4).
- [2]Alan E, Wakeling,Simon P, Guy,Jim R, Woodburn,etc.ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.[J].2002,62(20).
- [3]Y L, Wu,X, Yang,J-J, Yang,etc.ZD1839 for the treatment of heavily pretreated non-small cell lung cancer.[J].2004,22.
- [4]J D, Bergstr?m,B, Westermark,N E, Heldin.Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.[J].2000,259(1).